KOBAYASHI PHARMACEUTICAL  CO.,LTD. Logo

KOBAYASHI PHARMACEUTICAL CO.,LTD.

Manufactures OTC pharma, personal care, and household goods for niche consumer markets.

4967 | T

Overview

Corporate Details

ISIN(s):
JP3301100008
LEI:
Country:
Japan
Address:
大阪市中央区道修町4丁目4番10号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Kobayashi Pharmaceutical Co., Ltd. is a manufacturer and distributor of consumer products specializing in niche markets. The company's portfolio includes over-the-counter (OTC) pharmaceuticals, health and personal care items, and household goods. It is recognized for developing and marketing innovative products that address specific consumer needs and lifestyles, such as disposable body warmers, deodorizing air fresheners, and other personal wellness solutions. The company operates through various segments, including the manufacturing and sales of domestic household products.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-08 08:30
Report Publication Announcement
確認書
Japanese 8.1 KB
2025-08-08 08:30
Interim Report
半期報告書-第108期(2025/01/01-2025/12/31)
Japanese 226.4 KB
2025-03-31 08:27
Post-Annual General Meeting Information
臨時報告書
Japanese 25.4 KB
2025-03-28 07:33
Registration Form
確認書
Japanese 8.2 KB
2025-03-28 07:32
Governance Information
内部統制報告書-第107期(2024/01/01-2024/12/31)
Japanese 22.2 KB
2025-03-28 07:32
Annual Report
有価証券報告書-第107期(2024/01/01-2024/12/31)
Japanese 2.1 MB
2025-02-20 08:51
Post-Annual General Meeting Information
臨時報告書
Japanese 25.1 KB
2025-02-10 07:32
Legal Proceedings Report
訂正臨時報告書
Japanese 24.5 KB
2025-01-21 09:01
Board/Management Information
臨時報告書
Japanese 20.7 KB
2024-12-26 05:03
Major Shareholding Notification
臨時報告書
Japanese 20.5 KB
2024-11-08 07:41
Legal Proceedings Report
訂正臨時報告書
Japanese 24.1 KB
2024-08-09 08:00
Report Publication Announcement
確認書
Japanese 8.1 KB
2024-08-09 08:00
Interim Report
半期報告書-第107期(2024/01/01-2024/12/31)
Japanese 240.4 KB
2024-08-08 08:30
Legal Proceedings Report
訂正臨時報告書
Japanese 24.0 KB
2024-07-23 08:29
Board/Management Information
臨時報告書
Japanese 20.9 KB

Automate Your Workflow. Get a real-time feed of all KOBAYASHI PHARMACEUTICAL CO.,LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for KOBAYASHI PHARMACEUTICAL CO.,LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for KOBAYASHI PHARMACEUTICAL CO.,LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

LISATA THERAPEUTICS, INC. Logo
Oncology firm with a platform for more effective, targeted delivery of anti-cancer drugs.
United States of America
LSTA
LIXTE BIOTECHNOLOGY HOLDINGS, INC. Logo
Developing novel PP2A inhibitors to enhance cancer therapies and overcome treatment resistance.
United States of America
LIXT
Longeveron Inc. Logo
Develops cell therapies for Alzheimer's, aging frailty, and rare infant heart defects.
United States of America
LGVN
Lonza Group AG Logo
A leading CDMO for pharma, biotech & nutrition, providing end-to-end development & manufacturing.
Switzerland
LONN
Lyell Immunopharma, Inc. Logo
Develops durable CAR T-cell therapies for solid tumors & blood cancers by reprogramming T-cells.
United States of America
LYEL
Lyra Therapeutics, Inc. Logo
Developing localized, long-acting therapies for chronic rhinosinusitis (CRS).
United States of America
LYRA
Lytix Biopharma AS Logo
Develops oncolytic peptide immunotherapies that kill cancer and stimulate an anti-tumor response.
Norway
LYTIX
MaaT Pharma Logo
Developing gut microbiome therapies to improve survival for cancer patients.
France
MAAT
Mabion S.A. Logo
Global CDMO providing end-to-end services for developing and manufacturing complex biologic drugs.
Poland
MAB
MACROGENICS INC Logo
Biopharma firm developing innovative antibody-based therapeutics for cancer treatment.
United States of America
MGNX

Talk to a Data Expert

Have a question? We'll get back to you promptly.